Related Experiment Videos
[Antibody treatment for cancer]
S Sasaki1, I Ozeki, M Takekawa
1Department of Internal Medicine (Section 1), Sapporo Medical University, Japan.
Nihon Geka Gakkai Zasshi
|October 7, 2000
Summary
Engineered monoclonal antibodies overcome limitations of earlier cancer therapies. The new anti-erbB-2 antibody CH401 induces cancer cell death via apoptosis, showing promise for targeted cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Context:
- Early cancer therapy using murine monoclonal antibodies faced limitations due to short survival times and immune responses in humans.
- Genetically engineered antibodies, including chimeric and humanized forms, were developed to improve therapeutic efficacy.
- Overexpression of the erbB-2 oncogene is implicated in various cancers, including breast, ovarian, lung, and gastric.
Purpose:
- To develop and evaluate a novel anti-erbB-2 mouse-human chimeric monoclonal antibody (CH401) for cancer therapy.
- To investigate the mechanism of tumor growth inhibition mediated by CH401.
- To compare the cytotoxic mechanism of CH401 with other anti-erbB-2 antibodies.
Summary:
- The study generated the anti-erbB-2 mouse-human chimeric monoclonal antibody CH401.
- CH401 demonstrated the ability to kill cancer cells, with tumor growth inhibition primarily induced by apoptosis.
- The apoptotic mechanism of CH401 differs from previously reported anti-erbB-2 antibodies.
Impact:
- CH401 shows potential as a targeted cancer therapeutic agent, offering a novel mechanism of action.
- This research contributes to the advancement of antibody-based cancer therapies by addressing limitations of earlier approaches.
- The findings support the continued development of engineered monoclonal antibodies for effective cancer treatment.